Journal
NATURE REVIEWS CARDIOLOGY
Volume 8, Issue 4, Pages 187-188Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrcardio.2011.37
Keywords
-
Categories
Ask authors/readers for more resources
New therapeutic strategies are needed for patients with atherosclerosis. Despite failing to reach its primary end point, a multicenter, phase II, randomized, placebo-controlled trial of RVX-208-an oral, synthetic quinazoline molecule that stimulates expression of endogenous apolipoprotein A-I-has provided somewhat encouraging results. Nevertheless, detailed investigations are still needed if we are ever to realize the full atheroprotective potential of novel HDL-targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available